Court approves Chem Rx's first-day motions, allows normal business operations

Chem Rx Corporation (Pink Sheets: CHRX) ("Chem Rx"), the third largest long term care pharmacy in the United States, along with certain operating subsidiaries today announced that it has received Court approval for all of its first-day motions, allowing normal business operations, including the purchase and distribution of all drugs and services to its clients.  

The Court also approved on an interim basis Chem Rx's ability to access its cash and use it in its ongoing operations.  This approval allows the company to make payments to vendors for products and services purchased after the filing date of May 11, 2010.  The Court also approved the company's ability to pay employee wages, salaries and benefits both before and accruing after its voluntary petitions under Chapter 11.  

"Today's hearing was an important step in the reorganization process and we are pleased that the Court approved our first day motions," said Jerry Silva, Chem Rx CEO. "This will allow us to operate our business as usual, so that we can keep serving our many clients who rely on the drugs and supplies that we deliver each day for their patients."

SOURCE Chem Rx Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy